Ticagrelor API: A Comprehensive Guide to its Properties, Applications, and Benefits
Explore the advanced properties and crucial applications of Ticagrelor, a leading API for cardiovascular health.
Get a Quote & SampleProduct Core Value
Ticagrelor
Ticagrelor is a first-in-class, orally administered, potent, and reversible P2Y12 receptor antagonist. It is primarily used to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
- Discover the advanced Ticagrelor API uses in modern medicine, focusing on its role in preventing thrombotic events.
- Understand the critical Ticagrelor mechanism of action, highlighting its unique interaction with P2Y12 receptors.
- Learn about Ticagrelor antiplatelet therapy and its advantages over traditional treatments, offering superior protection.
- Explore the significant Ticagrelor cardiovascular benefits, contributing to improved patient outcomes and reduced mortality.
Advantages Provided by the Product
Superior Reversible Inhibition
Ticagrelor provides faster, greater, and more consistent inhibition of ADP-receptor compared to clopidogrel, offering enhanced protection against thrombotic events.
Broad Therapeutic Application
Its efficacy in reducing cardiovascular death and heart attack in patients with ACS makes it a vital component in critical cardiac care.
Favorable Pharmacokinetic Profile
Understanding Ticagrelor adverse effects and interactions is key to safe and effective patient management, ensuring optimal therapeutic outcomes.
Key Applications
Acute Coronary Syndrome Treatment
Ticagrelor plays a pivotal role in the treatment of acute coronary syndromes, significantly reducing the risk of major adverse cardiovascular events.
Post-Myocardial Infarction Management
For patients with a history of myocardial infarction, Ticagrelor offers long-term protection against recurrent thrombotic events.
Reducing Stent Thrombosis
It is effective in reducing the rate of stent thrombosis in patients who have undergone stenting procedures for ACS.
Comprehensive Cardiovascular Protection
This API contributes to overall cardiovascular health by inhibiting platelet aggregation and preventing blood clots.